Loading...
•
Sep 30, 2020
Alector Q3 2020 Earnings Report
Alector reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
Alector reported a net loss of $52.7 million for the quarter ended September 30, 2020, with $461.7 million in cash and investments. Collaboration revenue was $5.9 million, and the company is advancing its clinical programs, including the initiation of a Phase 3 trial for AL001.
Initiated Phase 3 AL001 trial in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).
On track to initiate Phase 2 study for AL002 in Alzheimer’s disease in 2020.
Collaboration revenue for the quarter ended September 30, 2020, was $5.9 million, compared to $2.7 million for the same period in 2019.
Cash, cash equivalents, and marketable securities were $461.7 million as of September 30, 2020.
Revenue by Segment
Forward Guidance
Alector believes that its cash and investments as of September 30, 2020, will be sufficient to fund its anticipated operations through 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...